Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.

Immuron Limited

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MELBOURNE, AUSTRALIA, JULY 16, 2026 (GLOBE NEWSWIRE) -- IMMURON LIMITED (ASX: IMC; NASDAQ: IMRN), AN AUSTRALIAN BASED AND GLOBALLY INTEGRATED BIOPHARMACEUTICAL COMPANY IS PLEASED TO ANNOUNCE CONTINUED SALES GROWTH (UNAUDITED) OF TRAVELAN, AN OVER-THE-COUNTER IMMUNE SUPPLEMENT THAT TARGETS PATHOGENIC BACTERIA AND THE TOXINS THEY PRODUCE IN THE GASTROINTESTINAL (GI) TRACT.

IMMURON FY26 SALES - FOUR CONSECUTIVE QUARTERS OF GROWTH OVER PRIOR YEAR

KEY POINTS IMMURON ENGAGES PULLAN CONSULTING TO ADVANCE IMM-529 PARTNERING STRATEGY IMMURON IS SEEKING A PARTNER TO SUPPORT CLINICAL DEVELOPMENT THROUGH REGULATORY APPROVAL AND COMMERCIALIZATION IMMURON HAS U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL FOR IMM-529 INVESTIGATIONAL NEW DRUG (IND) APPLICATION IND 32095 IS IMMURON'S INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR CLINICAL DEVELOPMENT OF IMM-529 AS A PRODUCT TO SPECIFICALLY PREVENT OR TREAT CLOSTRIDIOIDES DIFFICILE INFECTION (CDI) MELBOURNE, AUSTRALIA, JULY 06, 2026 (GLOBE NEWSWIRE) -- IMMURON LIMITED (ASX: IMC; NASDAQ: IMRN) IS PLEASED TO ANNOUNCE THAT IT HAS ENGAGED PULLAN CONSULTING TO PROVIDE BUSINESS DEVELOPMENT SERVICES TO ASSIST IN SECURING A STRATEGIC PARTNERSHIP FOR IMM-529. PULLAN CONSULTING IS A HIGHLY REGARDED LIFE SCIENCES ADVISORY FIRM WITH A STRONG TRACK RECORD OF EXECUTING BETWEEN FIVE AND TWELVE PARTNERING TRANSACTIONS ANNUALLY OVER THE PAST 20 YEARS.

IMMURON ADVANCES IMM-529 (CLOSTRIDIOIDES DIFFICILE INFECTION) PARTNERING STRATEGY

NEW YORK CITY, NY / ACCESS NEWSWIRE / APRIL 22, 2026 / EMERGING GROWTH RESEARCH TODAY RELEASED A FLASH REPORT ON IMMURON (NASDAQ:IMRN), MAINTAINING ITS BUY-EXTENDED RATING WHILE INCREASING ITS 12-MONTH PRICE TARGET TO $4.00 (FROM $3.90), REPRESENTING SIGNIFICANT UPSIDE FROM THE CURRENT SHARE PRICE OF $0.9268 AS OF APRIL 21, 2026. THE FLASH REPORT HIGHLIGHTS IMMURON'S CONTINUED REVENUE GROWTH, EXPANDING COMMERCIAL FOOTPRINT, AND PROGRESS WITHIN ITS CLINICAL DEVELOPMENT PIPELINE.

EMERGING GROWTH RESEARCH RELEASES FLASH REPORT ON IMMURON; MAINTAINS BUY-EXTENDED RATING AND RAISES PRICE TARGET TO $4.00

SALES HIGHLIGHTS (UNAUDITED): GLOBAL Q3 SALES AUD$1.5 MILLION UP 16% ON PRIOR COMPARATIVE PERIOD (PCP) YTD MAR 2026 SALES AUD$5.7 MILLION UP 7% ON PRIOR COMPARATIVE PERIOD (PCP) AUSTRALIA Q3 SALES AUD$0.9 MILLION UP 15% ON PRIOR COMPARATIVE PERIOD (PCP) YTD MAR 2026 SALES AUD$4.2 MILLION UP 14% ON PRIOR COMPARATIVE PERIOD (PCP) CANADA Q3 SALES AUD$0.1 MILLION UP >100% ON PRIOR COMPARATIVE PERIOD (PCP) Q3 SALES UP 82% ON PRIOR QUARTER; INITIAL SALES TO JEAN COUTU, QUEBEC YTD MAR 2026 SALES AUD$0.1 MILLION DOWN 65% ON PRIOR COMPARATIVE PERIOD (PCP) USA Q3 SALES AUD$0.5 MILLION UP 1% ON PRIOR COMPARATIVE PERIOD (PCP) YTD MAR 2026 SALES AUD$1.3 MILLION UP 10% ON PRIOR COMPARATIVE PERIOD (PCP) MELBOURNE, AUSTRALIA, APRIL 17, 2026 (GLOBE NEWSWIRE) -- IMMURON LIMITED (ASX: IMC; NASDAQ: IMRN), AN AUSTRALIAN BASED AND GLOBALLY INTEGRATED BIOPHARMACEUTICAL COMPANY IS PLEASED TO ANNOUNCE CONTINUED SALES GROWTH (UNAUDITED) OF TRAVELAN, AN OVER-THE-COUNTER IMMUNE SUPPLEMENT THAT TARGETS PATHOGENIC BACTERIA AND THE TOXINS THEY PRODUCE IN THE GASTROINTESTINAL (GI) TRACT. CONTINUED TRAVELAN Q3 SALES GROWTH ( +15% ON PCP) IN AUSTRALIA CAN BE CONTRIBUTED TO: (1) INCREASED AWARENESS AND CONSIDERATION DRIVEN BY EXTENSIVE DIGITAL AND SOCIAL MEDIA MARKETING.

IMMURON DOUBLE DIGIT 3Q SALES GROWTH

NEW YORK CITY, NEW YORK / ACCESS NEWSWIRE / MARCH 5, 2026 / EMERGING GROWTH RESEARCH TODAY RELEASED A FLASH RESEARCH UPDATE ON IMMURON LIMITED (NASDAQ:IMRN), MAINTAINING ITS BUY-EXTENDED RATING AND 12-MONTH PRICE TARGET OF $3.90 FOLLOWING THE COMPANY'S RELEASE OF FIRST-HALF FISCAL YEAR 2026 FINANCIAL RESULTS AND STRATEGIC UPDATE. THE FLASH REPORT NOTES THAT IMMURON REPORTED GLOBAL PRODUCT REVENUE OF AUD $4.18 MILLION FOR THE SIX MONTHS ENDED DECEMBER 31, 2025, REPRESENTING APPROXIMATELY 5% GROWTH COMPARED TO THE PRIOR-YEAR PERIOD.

EMERGING GROWTH RESEARCH ISSUES FLASH UPDATE ON IMMURON LIMITED, MAINTAINS BUY-EXTENDED RATING AND $3.90 PRICE TARGET

NEW YORK CITY, NY / ACCESS NEWSWIRE / JANUARY 22, 2026 / EMERGING GROWTH RESEARCH TODAY RELEASED A FLASH RESEARCH UPDATE ON IMMURON LIMITED (NASDAQ:IMRN), MAINTAINING ITS BUY-EXTENDED RATING AND 12-MONTH PRICE TARGET OF $3.50 FOLLOWING THE COMPANY'S RELEASE OF FIRST-HALF FISCAL YEAR 2026 OPERATING RESULTS. THE FLASH REPORT NOTES THAT IMMURON REPORTED GLOBAL REVENUE OF AUD$4.2 MILLION FOR THE SIX MONTHS ENDED DECEMBER 31, 2025, REPRESENTING A 5% INCREASE COMPARED TO THE PRIOR-YEAR PERIOD.

EMERGING GROWTH RESEARCH ISSUES FLASH UPDATE ON IMMURON LIMITED, MAINTAINS BUY-EXTENDED RATING AND $3.50 PRICE TARGET

SALES HIGHLIGHTS (UNAUDITED): GLOBAL H1 SALES AUD$4.2 MILLION UP 5% ON PRIOR COMPARATIVE PERIOD (PCP) Q2 SALES AUD$2.2 MILLION UP 11% ON PRIOR QUARTER AUSTRALIA H1 SALES AUD$3.3 MILLION UP 13% ON PRIOR COMPARATIVE PERIOD (PCP) Q2 SALES AUD$1.7 MILLION UP 11% ON PRIOR QUARTER AUSTRALIAN LAUNCH OF PROIBS CANADA H1 SALES AUD$56 THOUSAND DOWN 85% ON PRIOR COMPARATIVE PERIOD (PCP) Q2 SALES AUD$42 THOUSAND UP 191% ON PRIOR QUARTER USA H1 SALES AUD$0.9 MILLION UP 17% ON PRIOR COMPARATIVE PERIOD (PCP) Q2 SALES AUD$0.4 MILLION UP 8% ON PRIOR QUARTER MELBOURNE, AUSTRALIA, JAN. 19, 2026 (GLOBE NEWSWIRE) -- IMMURON LIMITED (ASX: IMC; NASDAQ: IMRN), AN AUSTRALIAN BASED AND GLOBALLY INTEGRATED BIOPHARMACEUTICAL COMPANY IS PLEASED TO ANNOUNCE CONTINUED SALES GROWTH (UNAUDITED) OF TRAVELAN, AN OVER-THE-COUNTER IMMUNE SUPPLEMENT THAT TARGETS PATHOGENIC BACTERIA AND THE TOXINS THEY PRODUCE IN THE GASTROINTESTINAL (GI) TRACT. CONTINUED TRAVELAN H1 SALES GROWTH ( +11% ON PCP) IN AUSTRALIA CAN BE CONTRIBUTED TO: (1) INCREASED AWARENESS AND CONSIDERATION DRIVEN BY EXTENSIVE DIGITAL AND SOCIAL MEDIA MARKETING; (2) SAME STORE GROWTH AS A RESULT OF INCREASED PROMOTION AND PAST PROMOTIONS DRIVING NEW CUSTOMERS AND RETURN CUSTOMERS RESPECTIVELY; (3) GROWTH FROM NEW STORES WITHIN BANNER GROUPS IN WHICH WE SECURED CORE RANGING IN FY25; (4) INCREASED SOUTH EAST ASIAN TRAVEL.

IMMURON REPORTS CONTINUED SALES GROWTH

KEY POINTS IMMURON RECEIVES U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL FOR IMM-529 INVESTIGATIONAL NEW DRUG (IND) APPLICATION AND CLINICAL STUDY MAY PROCEED FDA ASSIGNED AN IND NUMBER (032095) FOR THE IMM-529 APPLICATION IND 32095 IS IMMURON'S INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR CLINICAL DEVELOPMENT OF IMM-529 AS PRODUCT TO SPECIFICALLY PREVENT OR TREAT CLOSTRIDIOIDES DIFFICILE INFECTION (CDI) AND IS NOW ACTIVE MELBOURNE, AUSTRALIA, NOV. 05, 2025 (GLOBE NEWSWIRE) -- IMMURON LIMITED (ASX: IMC; NASDAQ: IMRN), IS PLEASED TO ANNOUNCE THAT THE UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED IMMURON'S INVESTIGATIONAL NEW DRUG APPLICATION FOR IMM-529 AND THE PHASE 2 CLINICAL TRIAL MAY PROCEED. THE COMPANY PLANS TO INITIATE A PHASE 2 CLINICAL TRIAL FOR IMM-529 IN INDIVIDUALS WITH CLOSTRIDIOIDES DIFFICILE INFECTION (CDI) DURING THE FIRST HALF OF 2026.

IMMURON IMM-529 IND APPROVED BY FDA

NEW YORK, NEW YORK--(NEWSFILE CORP. - OCTOBER 17, 2025) - EMERGING GROWTH RESEARCH TODAY ANNOUNCED THE INITIATION OF COVERAGE ON IMMURON LIMITED (NASDAQ: IMRN) WITH A BUY-EXTENDED RATING AND A 12-MONTH PRICE TARGET OF $4.00, REPRESENTING OVER 80% UPSIDE FROM THE COMPANY'S RECENT CLOSING PRICE OF $2.20. THE INITIATION REPORT HIGHLIGHTS IMMURON'S PROPRIETARY POLYCLONAL ANTIBODY PLATFORM, STRONG REVENUE GROWTH FROM ITS OVER-THE-COUNTER PRODUCT TRAVELAN, AND AN EXPANDING CLINICAL PIPELINE ADDRESSING MAJOR GLOBAL INFECTIOUS DISEASES.

EMERGING GROWTH RESEARCH INITIATES COVERAGE ON IMMURON LIMITED WITH A BUY-EXTENDED RATING AND $4.00 PRICE TARGET

SALES HIGHLIGHTS (UNAUDITED): GLOBAL  Q1 SALES AUD$2.0 MILLION UP 34% ON PRIOR COMPARATIVE PERIOD (PCP)    AUSTRALIA  Q1 SALES AUD$1.6 MILLION UP 52% ON PCP    CANADA  Q1 SALES AUD$0.0 MILLION DOWN 92% ON PCP    USA  Q1 SALES AUD$0.4 MILLION UP 44% ON PCP MELBOURNE, AUSTRALIA, OCT. 13, 2025 (GLOBE NEWSWIRE) -- IMMURON LIMITED (ASX: IMC; NASDAQ: IMRN), AN AUSTRALIAN BASED AND GLOBALLY INTEGRATED BIOPHARMACEUTICAL COMPANY IS PLEASED TO ANNOUNCE CONTINUED SALES GROWTH (UNAUDITED) OF TRAVELAN, AN OVER-THE-COUNTER IMMUNE SUPPLEMENT THAT TARGETS PATHOGENIC BACTERIA AND THE TOXINS THEY PRODUCE IN THE GASTROINTESTINAL (GI) TRACT. CONTINUED GROWTH ( +34% ON PCP) IN AUSTRALIA CAN BE CONTRIBUTED TO: (1) INCREASED AWARENESS AND CONSIDERATION DRIVEN BY EXTENSIVE DIGITAL AND SOCIAL MEDIA MARKETING.

Immuron Limited

IMRN

Price

Financial Reports

No items found.

Press Releases

Immuron Limited

IMRN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

IMRN